Contract facts
NONENo full NAICS 621511 intel page yet. Browse NAICS intelligence
PURCHASE OF ULTIMA GENOMICS REAGENTS, NEW PO is a federal NONE award for National Institutes Of Health Nhlbi held by Ultima Genomics, Inc. Estimated value $147K ($147K obligated). Current period of performance ends Aug 31, 2026. Last award drew 1 bidder. Place of performance: FREMONT CA.
PURCHASE OF ULTIMA GENOMICS REAGENTS, NEW PO
Recompete timing
PublicCurrent PoP ends Aug 31, 2026 (10 days remaining). Agencies typically plan 12–18 months ahead — at 0.3 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordUltima Genomics, Inc — $166K obligated across 2 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75N92025P00333?
75N92025P00333 (Purchase of ULTIMA genomics reagents NEW PO) is a National Institutes Of Health Nhlbi award with a potential value of $147K, currently held by Ultima Genomics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75N92025P00333?
National Institutes Of Health Nhlbi awarded 75N92025P00333 to Ultima Genomics, Inc (potential $147K).
Who is the incumbent on 75N92025P00333?
Ultima Genomics, Inc is the incumbent with $166K across 2 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2026.
When does Ultima Genomics, Inc’s 75N92025P00333 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.